TP53 and colonic neoplasm: Furthermore, β-cryptoxanthin in cooperation with oxaliplatin, a third-generation platinum-based chemotherapeutic drug, was found to induce apoptosis via negative regulation of a dominant-negative inhibitor of wild-type p53 and Tap73 (ΔNP73) in HCT116, SW480-ADH, and SW1417 colon cancer cells [141].